尼拉帕尼是一种强效PARP抑制剂，对铂敏感期的原发性和复发性卵巢癌的无进展生存期均有显著贡献，无论是否存在BRCA突变。具有可控制的副作用，特别是血液学方面的3-4级贫血，在近四分之一的患者中见到。据我们所知，尚未报道尼拉帕尼治疗引起的纯红细胞无形成症（PRCA）病例。一名65岁的女性被诊断为卵巢输卵管3期浆液性癌，并接受尼拉帕尼一线维持治疗，3个月后出现4级贫血。由于贫血无法缓解，需要输血，患者进行了骨髓穿刺活检。组织病理学评估一致性显示PRCA。在皮质类固醇治疗之后，血红蛋白计数恢复到正常范围。在日常实践中，应谨记尼拉帕尼引起的难治性贫血的潜在原因可能是PRCA，并可通过皮质类固醇治疗改善。

Niraparib, a strong poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor, contributed significantly to progression-free survival as a maintenance therapy in the platinum-sensitive period in both first-line and recurrent ovarian cancer, regardless of the BRCA mutation. Grade 3-4 anemia, which has a manageable side effect profile, especially hematological, is seen in almost 1 out of every 4 patients. To the best of our knowledge, there has been no reported case of pure red cell aplasia (PRCA) induced by niraparib treatment.A 65-year-old woman diagnosed with stage 3 serous carcinoma of the tuba received niraparib front-line maintenance treatment had grade 4 anemia after 3 months of niraparib treatment. She underwent bone marrow aspiration and biopsy because of refractory anemia, which needs red blood cell (RBC) transfusions despite interruption of treatment.The patient was treated with 1 mg/kg methyl prednisolone, after histopathological assessment was consistent with PRCA. The hemoglobin count returned to the normal range with steroid treatment.In daily practice, it should be kept in mind that in the case of refractory anemia induced by niraparib, the underlying cause might be PRCA and can be improved with steroid administration.